Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Published:2016-10 Issue:10 Volume:27 Page:1895-1902
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Joerger M.,von Pawel J.,Kraff S.,Fischer J.R.,Eberhardt W.,Gauler T.C.,Mueller L.,Reinmuth N.,Reck M.,Kimmich M.,Mayer F.,Kopp H.-G.,Behringer D.M.,Ko Y.-D.,Hilger R.A.,Roessler M.,Kloft C.,Henrich A.,Moritz B.,Miller M.C.,Salamone S.J.,Jaehde U.

Funder

Saladax Biomedical Inc

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/10/1895/7080208/mdw290.pdf

Reference20 articles.

1. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer;Belani;J Clin Oncol,2008

2. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings;Augusto;J Neurooncol,2008

3. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel;Hensing;Cancer,2003